Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

ABVC Biopharma Inc (ABVC)ABVC

Upturn stock ratingUpturn stock rating
ABVC Biopharma Inc
$0.55
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/06/2024: ABVC (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -56.96%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 18
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/06/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -56.96%
Avg. Invested days: 18
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/06/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 7.08M USD
Price to earnings Ratio -
1Y Target Price 2.02
Dividends yield (FY) -
Basic EPS (TTM) -1.66
Volume (30-day avg) 241356
Beta 0.81
52 Weeks Range 0.41 - 2.45
Updated Date 11/5/2024
Company Size Small-Cap Stock
Market Capitalization 7.08M USD
Price to earnings Ratio -
1Y Target Price 2.02
Dividends yield (FY) -
Basic EPS (TTM) -1.66
Volume (30-day avg) 241356
Beta 0.81
52 Weeks Range 0.41 - 2.45
Updated Date 11/5/2024

Earnings Date

Report Date 2024-11-13
When BeforeMarket
Estimate -
Actual -
Report Date 2024-11-13
When BeforeMarket
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -833.72%

Management Effectiveness

Return on Assets (TTM) -44.55%
Return on Equity (TTM) -320.36%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 9634511
Price to Sales(TTM) 60.11
Enterprise Value to Revenue 76.32
Enterprise Value to EBITDA -1.9
Shares Outstanding 12421800
Shares Floating 9137468
Percent Insiders 22.93
Percent Institutions 2.95
Trailing PE -
Forward PE -
Enterprise Value 9634511
Price to Sales(TTM) 60.11
Enterprise Value to Revenue 76.32
Enterprise Value to EBITDA -1.9
Shares Outstanding 12421800
Shares Floating 9137468
Percent Insiders 22.93
Percent Institutions 2.95

Analyst Ratings

Rating 3
Target Price 2.02
Buy -
Strong Buy -
Hold 1
Sell -
Strong Sell -
Rating 3
Target Price 2.02
Buy -
Strong Buy -
Hold 1
Sell -
Strong Sell -

AI Summarization

ABVC Biopharma Inc. - A Comprehensive Overview

Disclaimer: I am an AI chatbot and this information is for educational purposes only. It should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions.

Company Profile

Detailed history and background: ABVC Biopharma Inc. (ABVC) is a clinical-stage biopharmaceutical company focused on developing novel therapies for unmet medical needs in oncology and fibrosis. Founded in 2017 and headquartered in Fremont, California, ABVC utilizes its proprietary 3D bioprinting technology platform to create three-dimensional human tissues for drug discovery and development.

Core business areas: ABVC's core business areas include:

  • Oncology: Developing innovative cancer therapies targeting specific tumor types and resistant cancers.
  • Fibrosis: Focusing on treatments for fibrotic diseases affecting organs like the liver, lungs, and kidneys.
  • 3D Bioprinting: Utilizing its proprietary technology to create bioprinted human tissues for drug discovery and development.

Leadership team and corporate structure: ABVC's leadership team comprises experienced professionals in the pharmaceutical and biotech industry. The company operates a lean organizational structure with a focus on research and development.

Top Products and Market Share:

Top products and offerings: Currently, ABVC does not have any marketed products. However, its pipeline includes several promising drug candidates:

  • ABVC-001: A small molecule inhibitor targeting tyrosine kinases for the treatment of glioblastoma multiforme (GBM).
  • ABVC-002: A next-generation EGFR inhibitor for the treatment of non-small cell lung cancer (NSCLC).
  • ABVC-003: A first-in-class small molecule inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF).

Market share: As ABVC currently has no marketed products, it does not hold any market share in the global or US markets.

Product performance and market reception: All of ABVC's drug candidates are currently in preclinical or early clinical development stages. Therefore, it is too early to assess their market performance and reception.

Total Addressable Market:

The global oncology market is estimated to reach $260.8 billion by 2027, growing at a CAGR of 10.7%. The global fibrosis market is expected to reach $24.2 billion by 2028, with a CAGR of 9.3%. Thus, ABVC operates in large and growing addressable markets.

Financial Performance:

Revenue and net income: ABVC currently generates no revenue, as it is in the pre-revenue stage. Net income is also negative due to research and development expenses.

Profit margins and EPS: As ABVC has no revenue, it does not have profit margins or EPS.

Financial performance comparison: Year-over-year comparisons are not possible due to the short operational history.

Cash flow statements and balance sheet health: ABVC's cash flow is primarily from financing activities, as it is in the development stage. Its balance sheet is characterized by high cash reserves and minimal liabilities.

Dividends and Shareholder Returns:

Dividend history: ABVC does not currently pay dividends due to its focus on reinvesting capital for growth.

Shareholder returns: Shareholder returns are negative since ABVC's IPO in 2021.

Growth Trajectory:

Historical growth: ABVC has experienced rapid growth in recent years, driven by its promising pipeline and technology platform.

Future growth projections: Future growth projections are highly dependent on the success of its clinical trials and drug approvals.

Recent product launches and strategic initiatives: ABVC has recently initiated several clinical trials for its drug candidates. It has also entered into strategic partnerships with other companies to advance its research and development efforts.

Market Dynamics:

Industry trends: The oncology and fibrosis markets are characterized by innovation, with a focus on developing targeted therapies and personalized medicine.

Demand-supply scenarios: Demand for novel cancer and fibrosis treatments is high, but the supply of effective therapies remains limited.

Technological advancements: ABVC's 3D bioprinting technology platform has the potential to accelerate drug discovery and development.

Industry positioning and adaptability: ABVC is well-positioned with its innovative drug candidates and technology platform to adapt to changing market dynamics.

Competitors:

Key competitors:

  • In the oncology space: Amgen (AMGN), Bristol Myers Squibb (BMY), Pfizer (PFE)
  • In the fibrosis space: Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Genfit (GNFT)

Market share comparisons: ABVC has no market share as it has no marketed products.

Competitive advantages and disadvantages:

  • Advantages: Innovative drug candidates, proprietary 3D bioprinting technology.
  • Disadvantages: Pre-revenue stage, limited clinical data, intense competition.

Potential Challenges and Opportunities:

Key challenges:

  • Successfully completing clinical trials and obtaining regulatory approvals.
  • Achieving commercial success for its drug candidates.
  • Maintaining a strong financial position.

Potential opportunities:

  • Expanding its pipeline through internal research and development or acquisitions.
  • Partnering with other companies to accelerate drug development and commercialization.
  • Entering new markets with high unmet medical needs.

Recent Acquisitions:

ABVC has not made any acquisitions in the past 3 years.

AI-Based Fundamental Rating:

Rating: 7/10

Justification: ABVC has a strong pipeline of promising drug candidates and a unique technology platform. However, it is still in the early stages of development and faces significant challenges.

Sources and Disclaimers:

Sources:

Disclaimer: This information is for educational purposes only and should not be considered financial advice. Please consult a qualified financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About ABVC Biopharma Inc

Exchange NASDAQ Headquaters Fremont, CA, United States
IPO Launch date 2017-10-11 CEO & Interim CFO Dr. Uttam Yashwant Patil Ph.D.
Sector Healthcare Website https://www.abvcpharma.com
Industry Biotechnology Full time employees 16
Headquaters Fremont, CA, United States
CEO & Interim CFO Dr. Uttam Yashwant Patil Ph.D.
Website https://www.abvcpharma.com
Website https://www.abvcpharma.com
Full time employees 16

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​